---
title: "Prothena 10% owner William P. Scully buys 20,000 shares worth $157,990"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290222473.md"
description: "William P. Scully, a 10% owner of Prothena, purchased 20,000 ordinary shares at $7.90 each, totaling $157,990. This transaction increased his direct stake to 756,000 shares. The filing also notes indirect holdings of 80,000 shares via Manatee Equity Fund LLC and 52,000 shares held by his spouse."
datetime: "2026-06-18T15:39:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290222473.md)
  - [en](https://longbridge.com/en/news/290222473.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290222473.md)
---

# Prothena 10% owner William P. Scully buys 20,000 shares worth $157,990

-   Prothena 10% owner William P. Scully bought 20,000 ordinary shares at USD 7.9 each. \* His directly held stake rose to 756,000 ordinary shares. \* The filing also shows 80,000 ordinary shares held indirectly via Manatee Equity Fund LLC. \* It also reports 52,000 ordinary shares held indirectly by his spouse. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prothena Corporation plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001045463-26-000009), on June 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [PRTA.US](https://longbridge.com/en/quote/PRTA.US.md)

## Related News & Research

- [Prothena (PRTA) Expected to Announce Quarterly Earnings on Monday](https://longbridge.com/en/news/293914353.md)
- [Analyst Reiterates Buy on Prothena, Maintains $30 Price Target on Differentiated TTR-Depleter Opportunity](https://longbridge.com/en/news/293757628.md)
- [Eli Lilly (LLY) Stock Still Looks Cheap Following Its 407% Run](https://longbridge.com/en/news/293730498.md)
- [CU: Q2 2026 saw higher adjusted earnings and cash flow, with robust growth plans and regulatory wins](https://longbridge.com/en/news/294198350.md)
- [The Bull Case For Eli Lilly (LLY) Could Change Following Its Deeper Role In Illumina’s Billion Cell Atlas](https://longbridge.com/en/news/293269645.md)